FDA Approves Two New Drug Regimens for Hard to Treat Blood Cancers

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

This article covers new FDA-approved treatments for aggressive blood cancers like mantle cell lymphoma and leukemia.

First all-oral AML regimen.Inqovi offers older adults with newly diagnosed acute myeloid leukemia a chemotherapy-free option taken entirely at home. Before this, standard treatment required lengthy hospital stays for intravenous chemo, which many older patients could not tolerate.
New option after BTK failure.Beqalzi gives mantle cell lymphoma patients a targeted therapy after their cancer stopped responding to BTK inhibitors. Previously, these patients had few effective choices and faced a poor prognosis once BTK drugs failed.
Accelerated approval for urgent need.The FDA granted Beqalzi accelerated approval based on strong Phase I/II study results, meaning patients can access it now rather than waiting years for full trial completion. This matters because mantle cell lymphoma can progress rapidly with no standard next step.
Targeted therapy with fewer side effects.Beqalzi is a next generation BCL2 inhibitor designed to precisely kill cancer cells while sparing healthy ones. Unlike broad chemotherapy, this mechanism aims to reduce severe toxicities like infections and organ damage that often limit treatment duration.

The U.S. Food and Drug Administration has approved two new treatment options for patients with aggressive blood cancers, offering fresh hope for those with limited choices. One therapy targets relapsed mantle cell lymphoma, while the other provides the first all-oral regimen for older adults with newly diagnosed acute myeloid leukemia.

The FDA granted accelerated approval to Beqalzi (sonrotoclax), a next generation BCL2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma who have already tried at least two prior therapies including a BTK inhibitor. In a Phase I/II study presented at the 2025 American Society of Hematology Annual Meeting, the drug achieved an overall response rate of 52% and a complete response rate of 16%. Patients responded in a median of 1.9 months, and the median duration of response lasted 15.8 months. Treatment was generally well tolerated as a monotherapy. Continued approval depends on results from the ongoing Celestial-RRMCL Phase III trial.

Separately, the FDA approved Inqovi (decitabine and cedazuridine) in combination with venetoclax for adults with newly diagnosed acute myeloid leukemia who are 75 or older or who cannot tolerate intensive chemotherapy. This is the first and only all-oral combination approved for this population. The approval is based on the Phase II Ascertain-V study, where 41.6% of patients achieved complete remission with a median time to remission of two months. The median duration of complete remission had not yet been reached at the time of analysis. Inqovi uses cedazuridine to block an enzyme in the gut and liver, allowing oral delivery of decitabine at levels comparable to intravenous infusion. An estimated 22,720 Americans will be diagnosed with AML in 2026, and more than half may be ineligible for intensive chemotherapy. This all-oral option could reduce the need for frequent clinic visits for elderly or frail patients.

Both approvals mark significant progress for patients facing difficult to treat blood cancers. Researchers continue to study sonrotoclax in combination with other therapies for chronic lymphocytic leukemia, with data expected in 2026. For older AML patients, the new oral regimen offers a more convenient way to receive treatment at home. These advances reflect a growing focus on targeted, patient friendly therapies that aim to improve both outcomes and quality of life.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.